Switching From Anti-CD20 Therapy to Ublituximab Shows Promising Results in Phase 3b ENHANCE Trial

Press/Media

Period	7 Mar 2024

Media coverage

Title	Switching From Anti-CD20 Therapy to Ublituximab Shows Promising Results in Phase 3b ENHANCE Trial
Media name/outlet	Neurology Live
Country/Territory	United States
Date	7/03/24
URL	https://www.neurologylive.com/view/switching-anti-cd20-therapy-ublituximab-shows-promising-results-phase-3b-enhance-trial
Persons	Stephen C. Krieger